Clinical Trial Update: Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) [Phase 3]

View source ↗

Summary

This update describes an Asian Phase 3 trial evaluating Sacituzumab Govitecan (IMMU-132) for HR+/HER2- metastatic breast cancer, with the study currently active…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• TRODELVY (sacituzumab govitecan)

Snippet

Sponsor: Gilead Sciences | Conditions: Metastatic Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING